Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 3:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Bimekizumab Clear all
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

NCT06425549
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
bimekizumab, ustekinumab, placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
6 Years to 17 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
7
States / cities
Fountain Valley, California • Los Angeles, California • Northridge, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 28, 2026, 3:28 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

NCT06506916
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
Interventions
bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • Fountain Valley, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 28, 2026, 3:28 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis

NCT02905006
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Fremont, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 28, 2026, 3:28 PM EDT
Not yet recruiting Phase 2 Interventional

Efficacy of Bimekizumab in Adults With Pyoderma Gangrenosum

NCT07767864
View directory record Official record
Conditions
Pyoderma Gangrenosum
Interventions
Bimekizumab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 28, 2026, 3:28 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

NCT06624228
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab, Risankizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 28, 2026, 3:28 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

NCT03025542
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Bexley, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 28, 2026, 3:28 PM EDT
Completed Phase 4 Interventional

Bimekizumab in Plaque Psoriasis

NCT06336343
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Bimekizumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
East Windsor, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 28, 2026, 3:28 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

NCT04109976
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Boise, Idaho • Lexington, Kentucky • Baton Rouge, Louisiana + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 28, 2026, 3:28 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

NCT04718896
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana • Cypress, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 28, 2026, 3:28 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03536884
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions
Bimekizumab, Secukinumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Santa Ana, California • Danbury, Connecticut • Ocala, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 28, 2026, 3:28 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03598790
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
1,353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
48
States / cities
Glendale, Arizona • Phoenix, Arizona • Bakersfield, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 28, 2026, 3:28 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04242498
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
24
States / cities
Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 28, 2026, 3:28 PM EDT
Completed Phase 3 Interventional Results available

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03410992
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
San Diego, California • Santa Monica, California • Fort Myers, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 28, 2026, 3:28 PM EDT
Recruiting Phase 1 Interventional

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

NCT07290036
View directory record Official record
Conditions
Psoriatic Arthritis, Axial Spondyloarthritis
Interventions
Bimekizumab regimen 1 iv, Bimekizumab regimen 2 iv, Bimekizumab regimen 3 sc
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
30
States / cities
Peoria, Arizona • Apple Valley, California • Covina, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 28, 2026, 3:28 PM EDT
Not yet recruiting Phase 2 Interventional

A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)

NCT07766005
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
SPY072, Placebo, bimekizumab
Drug
Lead sponsor
Spyre Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Irvine, California • Indianapolis, Indiana • Bowling Green, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 28, 2026, 3:28 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420
View directory record Official record
Conditions
Palmoplantar Pustulosis
Interventions
Bimekizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Birmingham, Alabama • Fremont, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 28, 2026, 3:28 PM EDT
Not yet recruiting Phase 4 Interventional

Bimzelx (Bimekizumab) For The Treatment Of Adult Onset Pityriasis Rubra Pilaris (PRP)

NCT07497620
View directory record Official record
Conditions
Pityriasis Rubra Pilaris
Interventions
Bimekizumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 28, 2026, 3:28 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

NCT03766685
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Phoenix, Arizona • Bakersfield, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 28, 2026, 3:28 PM EDT
Recruiting Phase 1 Interventional

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

NCT06888193
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Santa Monica, California • South Miami, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 28, 2026, 3:28 PM EDT